Suzetrigine for Pain

Overseen By Medical Information

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Vertex Pharmaceuticals Incorporated

Disqualifiers: Illness, Sensitivity to SUZ, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

10 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the sensory attributes (basic tastes, aroma, texture, mouthfeel) of SUZ SDD and assess the impact of the dose on the sensory attributes.

Eligibility Criteria

This trial is for healthy adults who are trained and experienced in detecting, identifying, recognizing, and accurately describing different taste elements and flavor combinations. Specific qualifications based on sensory analysis skills are required.

Inclusion Criteria

I am trained and experienced in accurately identifying tastes and flavors.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive SUZ SDD to evaluate sensory attributes

1 day

1 visit (in-person)

Follow-up

Participants are monitored for any immediate reactions after treatment

1 week

Treatment Details

Interventions

• Suzetrigine (SUZ) Spray-dried Dispersion (SSD)

Trial Overview The study is testing the sensory attributes of Suzetrigine (SUZ) Spray-dried Dispersion (SSD), focusing on its basic tastes, aroma, texture, mouthfeel, and how these may change with different doses.

Participant Groups

Group I: SUZ Experimental Treatment 1 Intervention

Participants will be given SUZ SDD to retain in their mouths for approximately 10 seconds and then expectorate.

Who Is Running the Clinical Trial?

Vertex Pharmaceuticals Incorporated

Lead Sponsor

Trials

267

Recruited

36,100+

Dr. David Altshuler

Vertex Pharmaceuticals Incorporated

Chief Medical Officer since 2020

MD, PhD

Dr. Reshma Kewalramani

Vertex Pharmaceuticals Incorporated

Chief Executive Officer since 2020

MD, trained in internal medicine and nephrology